Signaling Gateway - 21 August 2009
http://links.ealert.nature.com/ctt?kn=19&m=33897845&r=MTc2ODc4NDI0MAS2&b=2&j=NTY5NTU1NTYS1&mt=1&rt=0
*********************************************************************
Signaling Update is a one-stop online resource designed to keep you
in touch with the latest and most exciting research in cell
signaling. New content is uploaded every Friday.
http://links.ealert.nature.com/ctt?kn=24&m=33897845&r=MTc2ODc4NDI0MAS2&b=2&j=NTY5NTU1NTYS1&mt=1&rt=0
*********************************************************************
Welcome to more choice.
Buy 4, get 2 FREE.
Choose from 200 newly released reagents, more sizes, and
fast, free, expert support in under 4 hours. Now choose any
4 fluorochrome or biotin-labeled antibodies from our entire
portfolio and choose 2 more FREE with no quantity limit.
Welcome to a more colorful world(SM). Visit bdbiosciences.com/choice
for more information.
http://links.ealert.nature.com/ctt?kn=1&m=33897845&r=MTc2ODc4NDI0MAS2&b=2&j=NTY5NTU1NTYS1&mt=1&rt=0
*********************************************************************
In Signaling Update this week:
------------------------
Featured Article
------------------------
KINASES: FREE UBIQUITIN!
The E3 ubiquitin ligase TRAF6 generates Lys63-linked unanchored
polyubiquitin chains that bind to the TAK1 and IKK complexes to
promote NF-kappaB activation.
Original research paper: Nature advance online publication,
12 August 2009
http://links.ealert.nature.com/ctt?kn=39&m=33897845&r=MTc2ODc4NDI0MAS2&b=2&j=NTY5NTU1NTYS1&mt=1&rt=0
-------------------
Selected Updates
-------------------
LIPID METABOLISM: AN 'IDOL' REGULATOR OF BLOOD CHOLESTEROL LEVELS
IDOL is an E3 ubiquitin ligase that targets the low-density
lipoprotein receptor (LDLR) for degradation.
Original research paper: Science 325, 100-104 (2009)
http://links.ealert.nature.com/ctt?kn=38&m=33897845&r=MTc2ODc4NDI0MAS2&b=2&j=NTY5NTU1NTYS1&mt=1&rt=0
ENDOCYTOSIS: INCREASED TRAFFICKING
GOLPH3 might activate mTOR signaling in cancer cell lines by
associating with the retromer complex and regulating receptor
recycling.
Original research paper: Nature 459, 1085-1090 (2009)
http://links.ealert.nature.com/ctt?kn=37&m=33897845&r=MTc2ODc4NDI0MAS2&b=2&j=NTY5NTU1NTYS1&mt=1&rt=0
OCULAR DISORDERS: SEEING THE POTENTIAL OF TARGETING CCR3
CC-chemokine receptor 3 (CCR3) signaling stimulates pathogenic blood
vessel growth in age-related macular degeneration (AMD), suggesting
that inhibition of CCR3 could help protect against severe AMD.
Original research paper: Nature 460, 225-230 (2009)
http://links.ealert.nature.com/ctt?kn=35&m=33897845&r=MTc2ODc4NDI0MAS2&b=2&j=NTY5NTU1NTYS1&mt=1&rt=0
More Updates:
http://links.ealert.nature.com/ctt?kn=34&m=33897845&r=MTc2ODc4NDI0MAS2&b=2&j=NTY5NTU1NTYS1&mt=1&rt=0
------------------------
Research Library
------------------------
http://links.ealert.nature.com/ctt?kn=33&m=33897845&r=MTc2ODc4NDI0MAS2&b=2&j=NTY5NTU1NTYS1&mt=1&rt=0
NEUROTRANSMISSION SELECTIVELY REGULATES SYNAPSE FORMATION IN
PARALLEL CIRCUITS IN VIVO
Nature 460, 1016-1020 (2009)
http://links.ealert.nature.com/ctt?kn=47&m=33897845&r=MTc2ODc4NDI0MAS2&b=2&j=NTY5NTU1NTYS1&mt=1&rt=0
PROLYL ISOMERASE PIN1 ACTS AS A SWITCH TO CONTROL THE DEGREE OF
SUBSTRATE UBIQUITYLATION
Nature Cell Biology 11, 967-972 (2009)
http://links.ealert.nature.com/ctt?kn=49&m=33897845&r=MTc2ODc4NDI0MAS2&b=2&j=NTY5NTU1NTYS1&mt=1&rt=0
STRUCTURAL AND FUNCTIONAL STUDIES OF THE RAS-ASSOCIATING AND
PLECKSTRIN-HOMOLOGY DOMAINS OF GRB10 AND GRB14
Nature Structural & Molecular Biology 16, 833-839 (2009)
http://links.ealert.nature.com/ctt?kn=30&m=33897845&r=MTc2ODc4NDI0MAS2&b=2&j=NTY5NTU1NTYS1&mt=1&rt=0
------------------------
Signaling News
------------------------
COLLINS SETS OUT HIS VISION FOR THE NIH
http://links.ealert.nature.com/ctt?kn=21&m=33897845&r=MTc2ODc4NDI0MAS2&b=2&j=NTY5NTU1NTYS1&mt=1&rt=0
Francis Collins, the new director of the US National Institutes of
Health (NIH) has laid out a five-point road map for the agency, which
includes focusing greater attention on translational research,
neglected diseases and health-care reform. However, Collins's top
priority will be tackling budget constraints after the $10.4-billion
boost from the economic stimulus package runs out in 2010.
More news
http://links.ealert.nature.com/ctt?kn=31&m=33897845&r=MTc2ODc4NDI0MAS2&b=2&j=NTY5NTU1NTYS1&mt=1&rt=0
-------------------------
Gateway Updates
-------------------------
NCI-NATURE PATHWAY INTERACTION DATABASE - AUGUST UPDATE
http://links.ealert.nature.com/ctt?kn=52&m=33897845&r=MTc2ODc4NDI0MAS2&b=2&j=NTY5NTU1NTYS1&mt=1&rt=0
The Pathway Interaction Database is a free, high-quality resource of
signaling pathways in human cells for biologists and
bioinformaticians to explore, visualize and mine signaling events.
This month's update features the HIF-2-alpha transcription factor
network and Nephrin/Neph1 signaling in the kidney podocyte.
Sign up here to receive the monthly update alert for the
NCI-Nature Pathway Interaction Database.
http://links.ealert.nature.com/ctt?kn=16&m=33897845&r=MTc2ODc4NDI0MAS2&b=2&j=NTY5NTU1NTYS1&mt=1&rt=0
-----------------------------
Job of the Week
-----------------------------
Principal Scientist
Employer: AstraZenca Pharmaceutical Innovation Center China
Location: Shanghai, China
http://links.ealert.nature.com/ctt?kn=9&m=33897845&r=MTc2ODc4NDI0MAS2&b=2&j=NTY5NTU1NTYS1&mt=1&rt=0
The AstraZeneca Innovation Center China (ICC) seeks a Principal
Scientist/Team Leader to manage pre-clinical research projects and
provide scientific strategies in support of global drug discovery and
development programs. The successful candidate will lead a research
group and coordinate with translational scientists to deliver
in vitro pharmacology data to support clinical development of
candidate drugs.
More Jobs:
http://links.ealert.nature.com/ctt?kn=10&m=33897845&r=MTc2ODc4NDI0MAS2&b=2&j=NTY5NTU1NTYS1&mt=1&rt=0
To advertise a job in this spot, please contact Naturejobs.
http://links.ealert.nature.com/ctt?kn=17&m=33897845&r=MTc2ODc4NDI0MAS2&b=2&j=NTY5NTU1NTYS1&mt=1&rt=0
======================================================================
Genentech is proud to be a corporate sponsor of the UCSD-Nature Signaling Gateway.
Genentech is a leading biotechnology company that discovers,
develops, manufactures and commercializes biotherapeutics
for significant unmet medical needs. Fifteen of the currently
approved biotechnology products stem from or are based on
Genentech science. Genentech manufactures and commercializes
ten biotechnology products directly in the United States.
The company has headquarters in South San Francisco, California,
and is traded on the New York Stock Exchange under the symbol DNA.
http://links.ealert.nature.com/ctt?kn=36&m=33897845&r=MTc2ODc4NDI0MAS2&b=2&j=NTY5NTU1NTYS1&mt=1&rt=0
=====================================================================
As a registered user of the Nature Publishing Group web sites, you
were selected to receive this message in the genuine belief that it
would be of interest to you.
If you no longer wish to receive news and announcements from Nature
Publishing Group or wish to unsubscribe from the Signaling Update
email alert please update your online Nature.com account details here:
http://links.ealert.nature.com/ctt?kn=5&m=33897845&r=MTc2ODc4NDI0MAS2&b=2&j=NTY5NTU1NTYS1&mt=1&rt=0
For further technical assistance or any other enquiries, please click here:
http://links.ealert.nature.com/ctt?kn=3&m=33897845&r=MTc2ODc4NDI0MAS2&b=2&j=NTY5NTU1NTYS1&mt=1&rt=0
Nature's world-wide offices:
London . Paris . Munich . New Delhi . Tokyo . Melbourne . San Diego .
San Francisco . Washington . New York . Boston
(c) 2009 Nature Publishing Group
---------------------------------------------------------------------
